GIP receptor activation improves insulin sensitivity and influences lipid metabolism
Semaglutide and tirzepatide are usually introduced with gradual dose escalation because gastrointestinal tolerability matters
Depending on the exact brand name drug, GLP-1s are FDA-approved to help manage type 2 diabetes, to facilitate weight management, or to help with both
Toxicon 56 , 855867 (2010)
Key effects often include: Increased fullness after eating Reduced hunger and cravings Slower stomach emptying (helps you feel full longer) Improved blood sugar regulation for many people GLP-1s are not a fit for everyone
By maintaining a microdose, patients may be able to achieve the desired effects of the drug while avoiding the dose threshold that triggers severe GI effects, resulting in a better overall experience and adherence to the treatment